1. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
   J. Chantharasamee et al, 2019, BMC Cancer CrossRef
2. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
   Min Peng et al, 2018, BioMed Research International CrossRef
3. DEVELOPMENT OF ERLOTINIB ENCAPSULATED SELF-ASSEMBLED MIXED MICELLES: OPTIMIZATION AND IN VITRO EVALUATION
   null null et al, 2023, INDIAN DRUGS CrossRef
4. EGFR mutations in non-small cell lung cancer: an audit from West China Hospital
   Yuan Tang et al, 2016, Expert Review of Molecular Diagnostics CrossRef
5. Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
   Yihan Ma et al, 2016, Oncotarget CrossRef
6. Loading and sustained release of sodium alginate membranes on pyridirubicin chloride
   Mengde Li et al, 2021, Materials Research Express CrossRef
7. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
   Sara Pilotto et al, 2018, Clinical Lung Cancer CrossRef
8. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway
   Yuyao Shen et al, 2019, Molecular and Cellular Probes CrossRef
9. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
   Alessandro Russo et al, 2019, International Journal of Molecular Sciences CrossRef